U.S. markets close in 6 hours 15 minutes

Dr. Reddy's Laboratories Limited (RDY)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
74.68+0.69 (+0.94%)
A partir del 09:43AM EDT. Mercado abierto.

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
India
91 40 4900 2900
https://www.drreddys.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo25,863

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management Council2.25MN/D1960
Mr. Kallam Satish Reddy B.Tech., M.S.Chairman of the Board & Member of the Management Council1.38MN/D1967
Mr. Erez Israeli M.B.A.CEO & Member of the Management CouncilN/DN/D1968
Mr. Parag AgarwalCFO & Member of Management CouncilN/DN/D1967
Mr. Deepak Sapra M.B.A.CEO of API & Services & Member of Management CouncilN/DN/D1975
Mr. Venkata Ramana Motupalli M.B.A.CEO of Branded Markets - India & Emerging Countries and Member of Management CouncilN/DN/D1969
Ms. Archana Bhaskar B.Sc., M.B.A.EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management CouncilN/DN/D1967
Mr. Sanjay Sharma B.Tech.Executive VP, Global Head of Global Manufacturing & Member of Management CouncilN/DN/D1968
Mr. Marc Kikuchi B.A., M.B.A.CEO of North America Generics & Member of Management CouncilN/DN/D1969
Mr. Patrick Aghanian B.A., M.B.A.CEO of European Generics & Member of Management CouncilN/DN/D1965
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Gestión corporativa

La calificación ISS Governance QuickScore de Dr. Reddy's Laboratories Limited a partir del 29 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 6; Junta: 3; Derechos del accionista: 1; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.